论文部分内容阅读
2012年12月,英国药品和健康产品管理局(MHRA)[1]对医务人员发出警告:欧裔和日裔患者应用卡马西平或奥卡西平所致严重的皮肤反应与HLA-A*3101等位基因有关,但现有证据不支持在开始卡马西平或奥卡西平治疗前检测患者该基因
In December 2012, the British Medicines and Health Products Authority (MHRA) [1] issued a warning to medical staff that European and Japanese patients had severe skin reactions caused by carbamazepine or oxcarbazepine in combination with HLA-A * 3101 Alleles, but the available evidence does not support the detection of patients with this gene before beginning carbamazepine or oxcarbazepine treatment